Accession Number:



Therapeutic Targeting of Neuroendocrine Prostate Cancer

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

University of Washington

Personal Author(s):

Report Date:


Pagination or Media Count:



Neuronedocrine prostate cancer is an advanced form of this disease with very limited option of effective treatment. It has been shown that BRN2 is highly expressed in NEPC, and preliminary in vitro data show that inhibition of BRN2 decreases tumor cells growth. We will perform preclinical evaluation of efficacy of a novel BRN2 inhibitor alone, in combination with carboplatin a standard therapy for neuroendocrine prostate cancer to determine whether this treatment inhibits progression of NEPC and provides survival benefits.

Subject Categories:

Distribution Statement:

[A, Approved For Public Release]